Table 1.

Essential thrombocythemia (ET) following primary immune thrombocytopenia (ITP). Bone marrow (BM) biopsy, dexamethasone (DXM) 40 mg/day × 4 days, intravenous immunoglobulin (IVIg), HD PDN: high dose prednisolone, ANA (anagrelide), HU (hydroxyurea), prednisone (PD), azathioprine (AZT), and acetylsalicylic acid (ASA). TTP (thrombotic thrombocytopenic purpura). (1): First line treatment, (2): second line treatment, (3): third line treatment, * allele burden, ** diagnosis of systemic lupus erythematosus (2013).

Authors	[1]	[2]	[3]	[4]	[5]	Observed Case
No	1	2	3	4	5	6
Gender	Female	Female	Female	Female	Female	Female
ITP diagnosis (in the age of)	January 2009 (14)	July 1992 (45)	March 2004 (72)	2004 (57)	2008 (64)	1997 (51)
ITP treatment	(1) DXM × 5 cycles (2) Splenectomy (August 2012): response	(1) PD × 3 (1st and 2nd relapse) After ET diagnosis: (2) 3rd ITP relapse: IVG + AZT (3) 4th ITP relapse: (4) PD + AZT: response	(1) PD: poor tolerance (2) PD +IVIG: poor efficacy and tolerance (3) splenectomy (March 2005): response	(1) HD PDN (2) splenectomy: response	(1) DXM: relapse DXM: response	(1) PD: no response (2) AZT: no response (3) Splenectomy (2004): response
ET diagnosis	August 2012	January 2013	January 2017	2011	February 2012	May 2015 **
Mutations	JAK2V617F: 11% *	JAK2V617F	JAK2V617F: 27% *	CALR exon 9 variant	JAK2V617F	TN
BM biopsy	Not done (patient refusal)	Compatible with ET (2013)	Compatible with ET (2017)	Compatible with ET	Compatible with ET	Compatible with ET
Interval between diagnosis of ITP and ET	3.5 years	21 years	13 years	7 years	4 years	18 years
ET treatment	No data	HU	HU	HU	HU + ASA	ANA